proxyvotesnow.com

Home › Companies › LINEAGE CELL THERAPEUTICS INC. › 2023-2024

LINEAGE CELL THERAPEUTICS INC. 2023-2024 Proxy Voting Records

Compiled from SEC Form N-PX filings and LINEAGE CELL THERAPEUTICS INC.’s Form 8-K, filed 2023-09-07 (Item 5.07 on EDGAR). Page generated 02 October 2026.

  • 25Reported items
  • 144Asset managers
  • 2,205Fund votes
  • 2023-09-06Main meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore LINEAGE CELL THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by LINEAGE CELL THERAPEUTICS INC.

These tallies are LINEAGE CELL THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2023-09-07 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX. LINEAGE CELL THERAPEUTICS INC. reported 2 meetings in this season; each is tabulated separately below, with its own filing.

LINEAGE CELL THERAPEUTICS INC. — official shareholder meeting results, meeting held 2023-09-06 (Form 8-K, filed 2023-09-07)
Ballot itemForAgainst AbstainWithheldBroker non-votesOutcome
Elect Director: Dipti Amin 74,273,372---- 1,103,02843,913,515 Majority: yes
Elect Director: Deborah Andrews 74,096,073---- 1,280,32743,913,515 Majority: yes
Elect Director: Don Bailey 73,391,291---- 1,985,10943,913,515 Majority: yes
Elect Director: Neal C. Bradsher 73,396,208---- 1,980,19243,913,515 Majority: yes
Elect Director: Brian M. Culley 74,426,506---- 949,89443,913,515 Majority: yes
Elect Director: Alfred D. Kingsley 71,157,090---- 4,219,31043,913,515 Majority: yes
Elect Director: Anula Jayasuriya 73,404,130---- 1,972,27043,913,515 Majority: yes
Elect Director: Michael H. Mulroy 63,115,746---- 12,260,65443,913,515 Majority: yes
Elect Director: Angus C. Russell 55,755,116---- 19,621,28443,913,515 Majority: yes
Proposal 4. The Company's shareholders voted as follows with respect to the preferred frequency of holding an advisory vote on the compensation of the Company's named executive officers. 66,175,9778,543,323657,100 --43,913,515 Majority: yes

Source: LINEAGE CELL THERAPEUTICS INC., Form 8-K, filed with the SEC on 2023-09-07 — read the filing on EDGAR.

LINEAGE CELL THERAPEUTICS INC. — official shareholder meeting results, meeting held 2024-06-11 (Form 8-K, filed 2024-06-13)
Ballot itemForAgainst AbstainWithheldBroker non-votesOutcome
Elect Director: Michael H. Mulroy 90,809,616---- 1,454,07339,856,522 Majority: yes
Elect Director: Dipti Amin 90,605,789---- 1,657,90039,856,522 Majority: yes
Elect Director: Deborah Andrews 90,481,681---- 1,782,00839,856,522 Majority: yes
Elect Director: Don M. Bailey 89,860,655---- 2,403,03439,856,522 Majority: yes
Elect Director: Neal C. Bradsher 90,181,941---- 2,080,75539,857,515 Majority: yes
Elect Director: Brian M. Culley 90,475,144---- 1,788,54539,856,522 Majority: yes
Elect Director: Anula Jayasuriya 89,952,809---- 2,310,88039,856,522 Majority: yes
Elect Director: Angus C. Russell 90,523,578---- 1,740,11139,856,522 Majority: yes
Proposal 2: Shareholders ratified the appointment of WithumSmith+Brown, PC as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 by the following votes: 128,607,9482,400,3221,111,941 ---- Majority: yes
Proposal 3: Shareholders approved, on an advisory basis, the compensation paid to the Company's named executive officers, as set forth in the Proxy Statement, by the following votes: 87,812,5983,704,495746,596 --39,856,522 Majority: yes

Source: LINEAGE CELL THERAPEUTICS INC., Form 8-K, filed with the SEC on 2024-06-13 — read the filing on EDGAR.

How asset managers voted at the LINEAGE CELL THERAPEUTICS INC. 2023-2024 meetings

Each item below shows how the 144 asset managers that disclosed a LINEAGE CELL THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of LINEAGE CELL THERAPEUTICS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. TO INDICATE, ON AN ADVISORY BASIS, THE PREFERRED FREQUENCY OF HOLDING AN ADVISORY VOTE ON THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Meeting held 2023-09-06.

Combines 5 wordings of this item as funds reported it.

89% Majority: yes · of votes cast

FOR 89%11%
FOR: 66,175,977AGAINST: 8,543,323

LINEAGE CELL THERAPEUTICS INC.’s own tally for this item (“Proposal 4. The Company's shareholders voted as follows with respect to the preferred frequency of holding an advisory vote on the compensation of the Company's named executive officers.”): 66,175,977 for, 8,543,323 against, per its Form 8-K filed 2023-09-07 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 174,986,671 outstanding shares: 38% for, 5% against (43% of the company cast a for/against vote).

The 106 asset managers below cast 99.7% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.

ONE YEAR 98%
FOR: 0.0%AGAINST: 0.0%ONE YEAR: 98.3%1 YEAR: 1.7%THREE YEARS: 0.0%3 YEARS: 0.0%1-YEAR: 0.0%
Largest asset managers voting on “TO INDICATE, ON AN ADVISORY BASIS, THE PREFERRED FREQUENCY OF HOLDING AN ADVISORY VOTE ON THE COMPENSATION OF ” at LINEAGE CELL THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Lazard00 00One Year
Vanguard00 00One Year
BlackRock00 00One Year
Laurion Capital Management LP00 00One Year
State Street00 00One Year
RAFFLES ASSOCIATES LP00 001 Year
GEODE CAPITAL MANAGEMENT, LLC00 00One Year
JPMorgan5,6800 00One Year
Fidelity00 00One Year
BRIDGEWAY FUNDS INC00 00One Year
Charles Schwab00 001 Year
MELLON INVESTMENTS Corp00 00One Year
Connor, Clark & Lunn Investment Management Ltd.00 00One Year
TIAA00 00One Year
Nuveen00 00One Year
QUANTITATIVE MASTER SERIES LLC00 00One Year
T. Rowe Price00 00One Year
Northern Trust00 00One Year
John Hancock00 00One Year
Lincoln Financial00 00One Year
Voya00 00One Year
DE Shaw00 00One Year
STIFEL NICOLAUS & CO INC \MO\00 00One Year
BANK OF AMERICA NA00 001 Year
NEW YORK STATE COMMON RETIREMENT FUND00 001 Year

Showing the 25 largest of 106 asset managers. See all 106 in the interactive database.

2. TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS.

SECTION 14A SAY-ON-PAY VOTES

Meeting held 2023-09-06.

Combines 4 wordings of this item as funds reported it.

99.4% fund support · no official result

FOR 99.4%

The 105 asset managers below cast 99.4% of the shares they voted on this item FOR (169,609,924 for, 912,461 against).

FOR: 169,609,924 (99.5%)AGAINST: 912,461 (0.5%)
Largest asset managers voting on “TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS.” at LINEAGE CELL THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Lazard148,000,0000 00For
Vanguard5,315,9470 00For
BlackRock5,177,7110 00For
Laurion Capital Management LP1,919,8340 00For
State Street1,828,5290 00For
RAFFLES ASSOCIATES LP1,597,7390 00For
GEODE CAPITAL MANAGEMENT, LLC1,081,9080 00For
Fidelity991,5360 00For
BRIDGEWAY FUNDS INC0767,100 00Against
Charles Schwab726,4300 00For
MELLON INVESTMENTS Corp301,6680 00For
Connor, Clark & Lunn Investment Management Ltd.242,4750 00For
TIAA201,5300 00For
Nuveen201,4450 00For
QUANTITATIVE MASTER SERIES LLC198,1740 00For
T. Rowe Price150,7870 00For
Northern Trust133,4150 00For
John Hancock121,8760 00For
Lincoln Financial115,6000 00For
Voya113,1900 00For
JPMorgan105,7390 00For
DE Shaw102,9630 00For
STIFEL NICOLAUS & CO INC \MO\102,0580 00For
BANK OF AMERICA NA70,0000 00For
NEW YORK STATE COMMON RETIREMENT FUND67,6000 00For

Showing the 25 largest of 105 asset managers. See all 105 in the interactive database.

3. TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS.

SECTION 14A SAY-ON-PAY VOTESCOMPENSATIONMajority of the votes cast: yes

Meeting held 2024-06-11.

Combines 4 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 87,812,598AGAINST: 3,704,495

LINEAGE CELL THERAPEUTICS INC.’s own tally for this item (“Proposal 3: Shareholders approved, on an advisory basis, the compensation paid to the Company's named executive officers, as set forth in the Proxy Statement, by the following votes:”): 87,812,598 for, 3,704,495 against, per its Form 8-K filed 2024-06-13 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 174,986,671 outstanding shares: 50.2% for, 2% against (52.3% of the company cast a for/against vote).

The 92 asset managers below cast 95% of the shares they voted on this item FOR (27,388,590 for, 1,322,495 against).

FOR 95%
FOR: 27,388,590 (95.4%)AGAINST: 1,322,495 (4.6%)
Largest asset managers voting on “TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS.” at LINEAGE CELL THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard6,637,2420 00For
Logos Global Management LP6,132,5540 00For
RAFFLES ASSOCIATES LP3,209,9810 00For
BlackRock3,107,5770 00For
DAFNA Capital Management LLC1,350,7080 00For
State Street1,139,7550 00For
Charles Schwab663,7210 00For
Northern Trust646,26120 00For
BRIDGEWAY CAPITAL MANAGEMENT, LLC0634,423 00Against
JPMorgan630,5360 00For
Prescott General Partners LLC620,0000 00For
BRIDGEWAY FUNDS INC0619,757 00Against
Wellington419,1550 00For
GEODE CAPITAL MANAGEMENT, LLC358,7360 00For
Fidelity354,4020 00For
RBC Capital Markets, LLC278,0000 00For
QUANTITATIVE MASTER SERIES LLC264,1910 00For
COMERICA BANK250,2950 00For
STIFEL NICOLAUS & CO INC \MO\202,0590 00For
Connor, Clark & Lunn Investment Management Ltd.200,3390 00For
MELLON INVESTMENTS Corp196,8780 00For
T. Rowe Price79,4050 00For
John Hancock77,9770 00For
Equitable61,8550 00For
Invesco050,160 00Against

Showing the 25 largest of 92 asset managers. See all 92 in the interactive database.

4. To elect nine directors to hold office until the 2024 annual meeting of shareholders and until their respective successors are duly elected and qualified: Alfred D. Kingsley

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2023-09-06.

Combines 3 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%
FOR: 71,157,090WITHHELD: 4,219,310

LINEAGE CELL THERAPEUTICS INC.’s own tally for this item (“Elect Director: Alfred D. Kingsley”): 71,157,090 for, 4,219,310 withheld, per its Form 8-K filed 2023-09-07 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 174,986,671 outstanding shares: 41% for, 2% withheld (43% of the company cast a for/withheld vote).

The 30 asset managers below cast 100% of the shares they voted on this item FOR (11,326,042 for, 0 against).

FOR 94%
FOR: 11,326,042 (93.6%)ABSTAIN: 768,400 (6.4%)
Largest asset managers voting on “To elect nine directors to hold office until the 2024 annual meeting of shareholders and until their respectiv” at LINEAGE CELL THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard5,221,1320 00For
BlackRock3,631,2040 00For
Fidelity988,8140 00For
BRIDGEWAY FUNDS INC00 767,1000Abstain
Charles Schwab363,2150 00For
TIAA201,4450 00For
QUANTITATIVE MASTER SERIES LLC198,1740 00For
Lincoln Financial115,6000 00For
Northern Trust68,9540 00For
T. Rowe Price65,4510 00For
AIG/SunAmerica62,1140 00For
John Hancock60,7230 00For
Voya56,5950 00For
State Street44,1970 00For
Equitable40,7170 00For
Brighthouse40,6900 00For
Pacific Life38,3140 00For
Bridge Builder Trust22,1330 00For
Nationwide21,7710 00For
DWS19,9320 00For
Amplify ETF Trust17,5930 00For
Principal15,2350 00For
Calvert10,6560 00For
PENN SERIES FUNDS INC5,1000 00For
ProShares5,0100 00For

Showing the 25 largest of 30 asset managers. See all 30 in the interactive database.

5. To elect nine directors to hold office until the 2024 annual meeting of shareholders and until their respective successors are duly elected and qualified: Angus C. Russell

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2023-09-06.

Combines 3 wordings of this item as funds reported it.

74% Majority: yes · of votes cast

FOR 74%WITHHELD 26%
FOR: 55,755,116WITHHELD: 19,621,284

LINEAGE CELL THERAPEUTICS INC.’s own tally for this item (“Elect Director: Angus C. Russell”): 55,755,116 for, 19,621,284 withheld, per its Form 8-K filed 2023-09-07 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 174,986,671 outstanding shares: 32% for, 11% withheld (43% of the company cast a for/withheld vote).

The 30 asset managers below cast 100% of the shares they voted on this item FOR (125,549 for, 0 against).

ABSTAIN 99%
FOR: 125,549 (1.0%)ABSTAIN: 11,968,893 (99.0%)
Largest asset managers voting on “To elect nine directors to hold office until the 2024 annual meeting of shareholders and until their respectiv” at LINEAGE CELL THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard00 5,221,1320Abstain
BlackRock00 3,631,2040Abstain
Fidelity00 988,8140Abstain
BRIDGEWAY FUNDS INC00 767,1000Abstain
Charles Schwab00 363,2150Abstain
TIAA00 201,4450Abstain
QUANTITATIVE MASTER SERIES LLC00 198,1740Abstain
Lincoln Financial00 115,6000Abstain
Northern Trust68,9540 00For
T. Rowe Price00 65,4510Abstain
AIG/SunAmerica00 62,1140Abstain
John Hancock00 60,7230Abstain
Voya56,5950 00For
State Street00 44,1970Abstain
Equitable00 40,7170Abstain
Brighthouse00 40,6900Abstain
Pacific Life00 38,3140Abstain
Bridge Builder Trust00 22,1330Abstain
Nationwide00 21,7710Abstain
DWS00 19,9320Abstain
Amplify ETF Trust00 17,5930Abstain
Principal00 15,2350Abstain
Calvert00 10,6560Abstain
PENN SERIES FUNDS INC00 5,1000Abstain
ProShares00 5,0100Abstain

Showing the 25 largest of 30 asset managers. See all 30 in the interactive database.

6. To elect nine directors to hold office until the 2024 annual meeting of shareholders and until their respective successors are duly elected and qualified: Anula Jayasuriya

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2023-09-06.

Combines 3 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%
FOR: 73,404,130WITHHELD: 1,972,270

LINEAGE CELL THERAPEUTICS INC.’s own tally for this item (“Elect Director: Anula Jayasuriya”): 73,404,130 for, 1,972,270 withheld, per its Form 8-K filed 2023-09-07 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 174,986,671 outstanding shares: 42% for, 1% withheld (43% of the company cast a for/withheld vote).

The 30 asset managers below cast 100% of the shares they voted on this item FOR (11,327,342 for, 0 against).

FOR 94%
FOR: 11,327,342 (93.7%)ABSTAIN: 767,100 (6.3%)
Largest asset managers voting on “To elect nine directors to hold office until the 2024 annual meeting of shareholders and until their respectiv” at LINEAGE CELL THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard5,221,1320 00For
BlackRock3,631,2040 00For
Fidelity988,8140 00For
BRIDGEWAY FUNDS INC00 767,1000Abstain
Charles Schwab363,2150 00For
TIAA201,4450 00For
QUANTITATIVE MASTER SERIES LLC198,1740 00For
Lincoln Financial115,6000 00For
Northern Trust68,9540 00For
T. Rowe Price65,4510 00For
AIG/SunAmerica62,1140 00For
John Hancock60,7230 00For
Voya56,5950 00For
State Street44,1970 00For
Equitable40,7170 00For
Brighthouse40,6900 00For
Pacific Life38,3140 00For
Bridge Builder Trust22,1330 00For
Nationwide21,7710 00For
DWS19,9320 00For
Amplify ETF Trust17,5930 00For
Principal15,2350 00For
Calvert10,6560 00For
PENN SERIES FUNDS INC5,1000 00For
ProShares5,0100 00For

Showing the 25 largest of 30 asset managers. See all 30 in the interactive database.

7. To elect nine directors to hold office until the 2024 annual meeting of shareholders and until their respective successors are duly elected and qualified: Brian M. Culley

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2023-09-06.

Combines 3 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%
FOR: 74,426,506WITHHELD: 949,894

LINEAGE CELL THERAPEUTICS INC.’s own tally for this item (“Elect Director: Brian M. Culley”): 74,426,506 for, 949,894 withheld, per its Form 8-K filed 2023-09-07 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 174,986,671 outstanding shares: 43% for, 0.6% withheld (43% of the company cast a for/withheld vote).

The 30 asset managers below cast 100% of the shares they voted on this item FOR (12,094,442 for, 0 against).

FOR 100%
FOR: 12,094,442 (100.0%)
Largest asset managers voting on “To elect nine directors to hold office until the 2024 annual meeting of shareholders and until their respectiv” at LINEAGE CELL THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard5,221,1320 00For
BlackRock3,631,2040 00For
Fidelity988,8140 00For
BRIDGEWAY FUNDS INC767,1000 00For
Charles Schwab363,2150 00For
TIAA201,4450 00For
QUANTITATIVE MASTER SERIES LLC198,1740 00For
Lincoln Financial115,6000 00For
Northern Trust68,9540 00For
T. Rowe Price65,4510 00For
AIG/SunAmerica62,1140 00For
John Hancock60,7230 00For
Voya56,5950 00For
State Street44,1970 00For
Equitable40,7170 00For
Brighthouse40,6900 00For
Pacific Life38,3140 00For
Bridge Builder Trust22,1330 00For
Nationwide21,7710 00For
DWS19,9320 00For
Amplify ETF Trust17,5930 00For
Principal15,2350 00For
Calvert10,6560 00For
PENN SERIES FUNDS INC5,1000 00For
ProShares5,0100 00For

Showing the 25 largest of 30 asset managers. See all 30 in the interactive database.

8. To elect nine directors to hold office until the 2024 annual meeting of shareholders and until their respective successors are duly elected and qualified: Deborah Andrews

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2023-09-06.

Combines 3 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 74,096,073WITHHELD: 1,280,327

LINEAGE CELL THERAPEUTICS INC.’s own tally for this item (“Elect Director: Deborah Andrews”): 74,096,073 for, 1,280,327 withheld, per its Form 8-K filed 2023-09-07 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 174,986,671 outstanding shares: 42% for, 0.8% withheld (43% of the company cast a for/withheld vote).

The 30 asset managers below cast 100% of the shares they voted on this item FOR (12,093,142 for, 0 against).

FOR 99.9%
FOR: 12,093,142 (100.0%)ABSTAIN: 1,300 (0.0%)
Largest asset managers voting on “To elect nine directors to hold office until the 2024 annual meeting of shareholders and until their respectiv” at LINEAGE CELL THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard5,221,1320 00For
BlackRock3,631,2040 00For
Fidelity988,8140 00For
BRIDGEWAY FUNDS INC767,1000 00For
Charles Schwab363,2150 00For
TIAA201,4450 00For
QUANTITATIVE MASTER SERIES LLC198,1740 00For
Lincoln Financial115,6000 00For
Northern Trust68,9540 00For
T. Rowe Price65,4510 00For
AIG/SunAmerica62,1140 00For
John Hancock60,7230 00For
Voya56,5950 00For
State Street44,1970 00For
Equitable40,7170 00For
Brighthouse40,6900 00For
Pacific Life38,3140 00For
Bridge Builder Trust22,1330 00For
Nationwide21,7710 00For
DWS19,9320 00For
Amplify ETF Trust17,5930 00For
Principal15,2350 00For
Calvert10,6560 00For
PENN SERIES FUNDS INC5,1000 00For
ProShares5,0100 00For

Showing the 25 largest of 30 asset managers. See all 30 in the interactive database.

9. To elect nine directors to hold office until the 2024 annual meeting of shareholders and until their respective successors are duly elected and qualified: Dipti Amin

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2023-09-06.

Combines 3 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%
FOR: 74,273,372WITHHELD: 1,103,028

LINEAGE CELL THERAPEUTICS INC.’s own tally for this item (“Elect Director: Dipti Amin”): 74,273,372 for, 1,103,028 withheld, per its Form 8-K filed 2023-09-07 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 174,986,671 outstanding shares: 42% for, 0.7% withheld (43% of the company cast a for/withheld vote).

The 30 asset managers below cast 100% of the shares they voted on this item FOR (12,093,142 for, 0 against).

FOR 99.9%
FOR: 12,093,142 (100.0%)ABSTAIN: 1,300 (0.0%)
Largest asset managers voting on “To elect nine directors to hold office until the 2024 annual meeting of shareholders and until their respectiv” at LINEAGE CELL THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard5,221,1320 00For
BlackRock3,631,2040 00For
Fidelity988,8140 00For
BRIDGEWAY FUNDS INC767,1000 00For
Charles Schwab363,2150 00For
TIAA201,4450 00For
QUANTITATIVE MASTER SERIES LLC198,1740 00For
Lincoln Financial115,6000 00For
Northern Trust68,9540 00For
T. Rowe Price65,4510 00For
AIG/SunAmerica62,1140 00For
John Hancock60,7230 00For
Voya56,5950 00For
State Street44,1970 00For
Equitable40,7170 00For
Brighthouse40,6900 00For
Pacific Life38,3140 00For
Bridge Builder Trust22,1330 00For
Nationwide21,7710 00For
DWS19,9320 00For
Amplify ETF Trust17,5930 00For
Principal15,2350 00For
Calvert10,6560 00For
PENN SERIES FUNDS INC5,1000 00For
ProShares5,0100 00For

Showing the 25 largest of 30 asset managers. See all 30 in the interactive database.

10. To elect nine directors to hold office until the 2024 annual meeting of shareholders and until their respective successors are duly elected and qualified: Don M. Bailey

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2023-09-06.

Combines 3 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%
FOR: 73,391,291WITHHELD: 1,985,109

LINEAGE CELL THERAPEUTICS INC.’s own tally for this item (“Elect Director: Don Bailey”): 73,391,291 for, 1,985,109 withheld, per its Form 8-K filed 2023-09-07 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 174,986,671 outstanding shares: 42% for, 1% withheld (43% of the company cast a for/withheld vote).

The 30 asset managers below cast 100% of the shares they voted on this item FOR (11,327,342 for, 0 against).

FOR 94%
FOR: 11,327,342 (93.7%)ABSTAIN: 767,100 (6.3%)
Largest asset managers voting on “To elect nine directors to hold office until the 2024 annual meeting of shareholders and until their respectiv” at LINEAGE CELL THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard5,221,1320 00For
BlackRock3,631,2040 00For
Fidelity988,8140 00For
BRIDGEWAY FUNDS INC00 767,1000Abstain
Charles Schwab363,2150 00For
TIAA201,4450 00For
QUANTITATIVE MASTER SERIES LLC198,1740 00For
Lincoln Financial115,6000 00For
Northern Trust68,9540 00For
T. Rowe Price65,4510 00For
AIG/SunAmerica62,1140 00For
John Hancock60,7230 00For
Voya56,5950 00For
State Street44,1970 00For
Equitable40,7170 00For
Brighthouse40,6900 00For
Pacific Life38,3140 00For
Bridge Builder Trust22,1330 00For
Nationwide21,7710 00For
DWS19,9320 00For
Amplify ETF Trust17,5930 00For
Principal15,2350 00For
Calvert10,6560 00For
PENN SERIES FUNDS INC5,1000 00For
ProShares5,0100 00For

Showing the 25 largest of 30 asset managers. See all 30 in the interactive database.

11. To elect nine directors to hold office until the 2024 annual meeting of shareholders and until their respective successors are duly elected and qualified: Michael H. Mulroy

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2023-09-06.

Combines 3 wordings of this item as funds reported it.

84% Majority: yes · of votes cast

FOR 84%WITHHELD 16%
FOR: 63,115,746WITHHELD: 12,260,654

LINEAGE CELL THERAPEUTICS INC.’s own tally for this item (“Elect Director: Michael H. Mulroy”): 63,115,746 for, 12,260,654 withheld, per its Form 8-K filed 2023-09-07 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 174,986,671 outstanding shares: 36% for, 7% withheld (43% of the company cast a for/withheld vote).

The 30 asset managers below cast 100% of the shares they voted on this item FOR (5,671,015 for, 0 against).

FOR 46.9%ABSTAIN 53.1%
FOR: 5,671,015 (46.9%)ABSTAIN: 6,423,427 (53.1%)
Largest asset managers voting on “To elect nine directors to hold office until the 2024 annual meeting of shareholders and until their respectiv” at LINEAGE CELL THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard5,221,1320 00For
BlackRock00 3,631,2040Abstain
Fidelity00 988,8140Abstain
BRIDGEWAY FUNDS INC00 767,1000Abstain
Charles Schwab00 363,2150Abstain
TIAA201,4450 00For
QUANTITATIVE MASTER SERIES LLC00 198,1740Abstain
Lincoln Financial111,3000 4,3000For
Northern Trust68,9540 00For
T. Rowe Price00 65,4510Abstain
AIG/SunAmerica00 62,1140Abstain
John Hancock00 60,7230Abstain
Voya00 56,5950Abstain
State Street44,1970 00For
Equitable1,2940 39,4230Abstain
Brighthouse00 40,6900Abstain
Pacific Life00 38,3140Abstain
Bridge Builder Trust00 22,1330Abstain
Nationwide00 21,7710Abstain
DWS00 19,9320Abstain
Amplify ETF Trust17,5930 00For
Principal00 15,2350Abstain
Calvert00 10,6560Abstain
PENN SERIES FUNDS INC5,1000 00For
ProShares00 5,0100Abstain

Showing the 25 largest of 30 asset managers. See all 30 in the interactive database.

12. To elect nine directors to hold office until the 2024 annual meeting of shareholders and until their respective successors are duly elected and qualified: Neal C. Bradsher

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2023-09-06.

Combines 3 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%
FOR: 73,396,208WITHHELD: 1,980,192

LINEAGE CELL THERAPEUTICS INC.’s own tally for this item (“Elect Director: Neal C. Bradsher”): 73,396,208 for, 1,980,192 withheld, per its Form 8-K filed 2023-09-07 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 174,986,671 outstanding shares: 42% for, 1% withheld (43% of the company cast a for/withheld vote).

The 30 asset managers below cast 100% of the shares they voted on this item FOR (11,315,386 for, 0 against).

FOR 94%
FOR: 11,315,386 (93.6%)ABSTAIN: 779,056 (6.4%)
Largest asset managers voting on “To elect nine directors to hold office until the 2024 annual meeting of shareholders and until their respectiv” at LINEAGE CELL THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard5,221,1320 00For
BlackRock3,631,2040 00For
Fidelity988,8140 00For
BRIDGEWAY FUNDS INC00 767,1000Abstain
Charles Schwab363,2150 00For
TIAA201,4450 00For
QUANTITATIVE MASTER SERIES LLC198,1740 00For
Lincoln Financial115,6000 00For
Northern Trust68,9540 00For
T. Rowe Price65,4510 00For
AIG/SunAmerica62,1140 00For
John Hancock60,7230 00For
Voya56,5950 00For
State Street44,1970 00For
Equitable40,7170 00For
Brighthouse40,6900 00For
Pacific Life38,3140 00For
Bridge Builder Trust22,1330 00For
Nationwide21,7710 00For
DWS19,9320 00For
Amplify ETF Trust17,5930 00For
Principal15,2350 00For
Calvert00 10,6560Abstain
PENN SERIES FUNDS INC5,1000 00For
ProShares5,0100 00For

Showing the 25 largest of 30 asset managers. See all 30 in the interactive database.

13. TO APPROVE AN AMENDMENT TO OUR ARTICLES OF INCORPORATION TO INCREASE THE NUMBER OF OUR AUTHORIZED COMMON SHARES FROM 250,000,000 TO 450,000,000.

CAPITAL STRUCTURE

Meeting held 2023-09-06.

Combines 2 wordings of this item as funds reported it.

100% fund support · no official result

FOR 100%

The 30 asset managers below cast 100% of the shares they voted on this item FOR (12,094,442 for, 0 against).

FOR: 12,094,442 (100.0%)
Largest asset managers voting on “TO APPROVE AN AMENDMENT TO OUR ARTICLES OF INCORPORATION TO INCREASE THE NUMBER OF OUR AUTHORIZED COMMON SHARE” at LINEAGE CELL THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard5,221,1320 00For
BlackRock3,631,2040 00For
Fidelity988,8140 00For
BRIDGEWAY FUNDS INC767,1000 00For
Charles Schwab363,2150 00For
TIAA201,4450 00For
QUANTITATIVE MASTER SERIES LLC198,1740 00For
Lincoln Financial115,6000 00For
Northern Trust68,9540 00For
T. Rowe Price65,4510 00For
AIG/SunAmerica62,1140 00For
John Hancock60,7230 00For
Voya56,5950 00For
State Street44,1970 00For
Equitable40,7170 00For
Brighthouse40,6900 00For
Pacific Life38,3140 00For
Bridge Builder Trust22,1330 00For
Nationwide21,7710 00For
DWS19,9320 00For
Amplify ETF Trust17,5930 00For
Principal15,2350 00For
Calvert10,6560 00For
PENN SERIES FUNDS INC5,1000 00For
ProShares5,0100 00For

Showing the 25 largest of 30 asset managers. See all 30 in the interactive database.

14. TO APPROVE AN AMENDMENT TO THE LINEAGE CELL THERAPEUTICS, INC. 2021 EQUITY INCENTIVE PLAN TO INCREASE THE NUMBER OF COMMON SHARES AVAILABLE THEREUNDER BY 19,500,000.

COMPENSATION

Meeting held 2023-09-06.

Combines 2 wordings of this item as funds reported it.

90% fund support · no official result

FOR 90%10%

The 30 asset managers below cast 90% of the shares they voted on this item FOR (10,914,188 for, 1,180,254 against).

FOR: 10,914,188 (90.2%)AGAINST: 1,180,254 (9.8%)
Largest asset managers voting on “TO APPROVE AN AMENDMENT TO THE LINEAGE CELL THERAPEUTICS, INC. 2021 EQUITY INCENTIVE PLAN TO INCREASE THE NUMB” at LINEAGE CELL THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard5,221,1320 00For
BlackRock3,631,2040 00For
Fidelity0988,814 00Against
BRIDGEWAY FUNDS INC767,1000 00For
Charles Schwab363,2150 00For
TIAA201,4450 00For
QUANTITATIVE MASTER SERIES LLC198,1740 00For
Lincoln Financial4,300111,300 00Against
Northern Trust68,9540 00For
T. Rowe Price65,4510 00For
AIG/SunAmerica62,1140 00For
John Hancock60,7230 00For
Voya56,5950 00For
State Street044,197 00Against
Equitable39,4231,294 00For
Brighthouse40,6900 00For
Pacific Life38,3140 00For
Bridge Builder Trust22,1330 00For
Nationwide21,7710 00For
DWS19,9320 00For
Amplify ETF Trust017,593 00Against
Principal15,2350 00For
Calvert010,656 00Against
PENN SERIES FUNDS INC05,100 00Against
ProShares5,0100 00For

Showing the 25 largest of 30 asset managers. See all 30 in the interactive database.

15. TO APPROVE THE ADJOURNMENT OF THE MEETING, IF NECESSARY OR ADVISABLE, TO SOLICIT ADDITIONAL PROXIES IN FAVOR OF PROPOSAL 6 IF THERE ARE NOT SUFFICIENT VOTES TO APPROVE PROPOSAL 6.

CORPORATE GOVERNANCE

Meeting held 2023-09-06.

Combines 2 wordings of this item as funds reported it.

98% fund support · no official result

FOR 98%

The 30 asset managers below cast 98% of the shares they voted on this item FOR (11,868,394 for, 226,048 against).

FOR: 11,868,394 (98.1%)AGAINST: 226,048 (1.9%)
Largest asset managers voting on “TO APPROVE THE ADJOURNMENT OF THE MEETING, IF NECESSARY OR ADVISABLE, TO SOLICIT ADDITIONAL PROXIES IN FAVOR O” at LINEAGE CELL THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard5,221,1320 00For
BlackRock3,631,2040 00For
Fidelity988,8140 00For
BRIDGEWAY FUNDS INC767,1000 00For
Charles Schwab363,2150 00For
TIAA201,4450 00For
QUANTITATIVE MASTER SERIES LLC198,1740 00For
Lincoln Financial4,300111,300 00Against
Northern Trust68,9540 00For
T. Rowe Price065,451 00Against
AIG/SunAmerica62,1140 00For
John Hancock60,7230 00For
Voya56,5950 00For
State Street044,197 00Against
Equitable40,7170 00For
Brighthouse40,6900 00For
Pacific Life38,3140 00For
Bridge Builder Trust22,1330 00For
Nationwide21,7710 00For
DWS19,9320 00For
Amplify ETF Trust17,5930 00For
Principal15,2350 00For
Calvert10,6560 00For
PENN SERIES FUNDS INC05,100 00Against
ProShares5,0100 00For

Showing the 25 largest of 30 asset managers. See all 30 in the interactive database.

16. To ratify the appointment of WithumSmith+Brown, PC as our independent registered public accounting firm for our fiscal year ending December 31, 2023.

AUDIT-RELATED

Meeting held 2023-09-06.

Combines 3 wordings of this item as funds reported it.

100% fund support · no official result

FOR 100%

The 30 asset managers below cast 100% of the shares they voted on this item FOR (12,094,442 for, 0 against).

FOR: 12,094,442 (100.0%)
Largest asset managers voting on “To ratify the appointment of WithumSmith+Brown, PC as our independent registered public accounting firm for ou” at LINEAGE CELL THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard5,221,1320 00For
BlackRock3,631,2040 00For
Fidelity988,8140 00For
BRIDGEWAY FUNDS INC767,1000 00For
Charles Schwab363,2150 00For
TIAA201,4450 00For
QUANTITATIVE MASTER SERIES LLC198,1740 00For
Lincoln Financial115,6000 00For
Northern Trust68,9540 00For
T. Rowe Price65,4510 00For
AIG/SunAmerica62,1140 00For
John Hancock60,7230 00For
Voya56,5950 00For
State Street44,1970 00For
Equitable40,7170 00For
Brighthouse40,6900 00For
Pacific Life38,3140 00For
Bridge Builder Trust22,1330 00For
Nationwide21,7710 00For
DWS19,9320 00For
Amplify ETF Trust17,5930 00For
Principal15,2350 00For
Calvert10,6560 00For
PENN SERIES FUNDS INC5,1000 00For
ProShares5,0100 00For

Showing the 25 largest of 30 asset managers. See all 30 in the interactive database.

17. To elect eight directors to hold office until the 2025 annual meeting of shareholders and until their respective successors are duly elected and qualified: Angus C. Russell

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2024-06-11.

Combines 3 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 90,523,578WITHHELD: 1,740,111

LINEAGE CELL THERAPEUTICS INC.’s own tally for this item (“Elect Director: Angus C. Russell”): 90,523,578 for, 1,740,111 withheld, per its Form 8-K filed 2024-06-13 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 174,986,671 outstanding shares: 51.7% for, 1.0% withheld (52.7% of the company cast a for/withheld vote).

The 29 asset managers below cast 100% of the shares they voted on this item FOR (9,426,299 for, 0 against).

FOR 99.9%
FOR: 9,426,299 (100.0%)ABSTAIN: 1,300 (0.0%)
Largest asset managers voting on “To elect eight directors to hold office until the 2025 annual meeting of shareholders and until their respecti” at LINEAGE CELL THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard6,355,4300 00For
BlackRock1,007,0020 00For
BRIDGEWAY FUNDS INC619,7570 00For
Charles Schwab365,9520 00For
Fidelity352,3870 00For
QUANTITATIVE MASTER SERIES LLC264,1910 00For
Lincoln Financial115,6000 00For
Equitable65,6450 00For
John Hancock55,0530 00For
Pacific Life38,3140 00For
T. Rowe Price26,2850 00For
Bridge Builder Trust26,1290 00For
DWS19,9320 00For
AIG/SunAmerica19,7080 00For
Principal17,8510 00For
Nationwide13,8620 00For
ProShares12,0550 00For
Calvert10,6560 00For
Victory Capital10,1700 00For
State Street9,4010 00For
TIAA5,1560 00For
PENN SERIES FUNDS INC5,1000 00For
Morgan Stanley4,0620 00For
Guggenheim2,5850 00For
Brinker Capital Destinations Trust2,2630 00For

Showing the 25 largest of 29 asset managers. See all 29 in the interactive database.

18. To elect eight directors to hold office until the 2025 annual meeting of shareholders and until their respective successors are duly elected and qualified: Anula Jayasuriya

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2024-06-11.

Combines 3 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%
FOR: 89,952,809WITHHELD: 2,310,880

LINEAGE CELL THERAPEUTICS INC.’s own tally for this item (“Elect Director: Anula Jayasuriya”): 89,952,809 for, 2,310,880 withheld, per its Form 8-K filed 2024-06-13 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 174,986,671 outstanding shares: 51.4% for, 1% withheld (52.7% of the company cast a for/withheld vote).

The 29 asset managers below cast 100% of the shares they voted on this item FOR (8,807,842 for, 0 against).

FOR 93%
FOR: 8,807,842 (93.4%)ABSTAIN: 619,757 (6.6%)
Largest asset managers voting on “To elect eight directors to hold office until the 2025 annual meeting of shareholders and until their respecti” at LINEAGE CELL THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard6,355,4300 00For
BlackRock1,007,0020 00For
BRIDGEWAY FUNDS INC00 619,7570Abstain
Charles Schwab365,9520 00For
Fidelity352,3870 00For
QUANTITATIVE MASTER SERIES LLC264,1910 00For
Lincoln Financial115,6000 00For
Equitable65,6450 00For
John Hancock55,0530 00For
Pacific Life38,3140 00For
T. Rowe Price26,2850 00For
Bridge Builder Trust26,1290 00For
DWS19,9320 00For
AIG/SunAmerica19,7080 00For
Principal17,8510 00For
Nationwide13,8620 00For
ProShares12,0550 00For
Calvert10,6560 00For
Victory Capital10,1700 00For
State Street9,4010 00For
TIAA5,1560 00For
PENN SERIES FUNDS INC5,1000 00For
Morgan Stanley4,0620 00For
Guggenheim2,5850 00For
Brinker Capital Destinations Trust2,2630 00For

Showing the 25 largest of 29 asset managers. See all 29 in the interactive database.

19. To elect eight directors to hold office until the 2025 annual meeting of shareholders and until their respective successors are duly elected and qualified: Brian M. Culley

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2024-06-11.

Combines 3 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 90,475,144WITHHELD: 1,788,545

LINEAGE CELL THERAPEUTICS INC.’s own tally for this item (“Elect Director: Brian M. Culley”): 90,475,144 for, 1,788,545 withheld, per its Form 8-K filed 2024-06-13 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 174,986,671 outstanding shares: 51.7% for, 1% withheld (52.7% of the company cast a for/withheld vote).

The 29 asset managers below cast 100% of the shares they voted on this item FOR (9,427,599 for, 0 against).

FOR 100%
FOR: 9,427,599 (100.0%)
Largest asset managers voting on “To elect eight directors to hold office until the 2025 annual meeting of shareholders and until their respecti” at LINEAGE CELL THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard6,355,4300 00For
BlackRock1,007,0020 00For
BRIDGEWAY FUNDS INC619,7570 00For
Charles Schwab365,9520 00For
Fidelity352,3870 00For
QUANTITATIVE MASTER SERIES LLC264,1910 00For
Lincoln Financial115,6000 00For
Equitable65,6450 00For
John Hancock55,0530 00For
Pacific Life38,3140 00For
T. Rowe Price26,2850 00For
Bridge Builder Trust26,1290 00For
DWS19,9320 00For
AIG/SunAmerica19,7080 00For
Principal17,8510 00For
Nationwide13,8620 00For
ProShares12,0550 00For
Calvert10,6560 00For
Victory Capital10,1700 00For
State Street9,4010 00For
TIAA5,1560 00For
PENN SERIES FUNDS INC5,1000 00For
Morgan Stanley4,0620 00For
Guggenheim2,5850 00For
Brinker Capital Destinations Trust2,2630 00For

Showing the 25 largest of 29 asset managers. See all 29 in the interactive database.

20. To elect eight directors to hold office until the 2025 annual meeting of shareholders and until their respective successors are duly elected and qualified: Deborah Andrews

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2024-06-11.

Combines 3 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 90,481,681WITHHELD: 1,782,008

LINEAGE CELL THERAPEUTICS INC.’s own tally for this item (“Elect Director: Deborah Andrews”): 90,481,681 for, 1,782,008 withheld, per its Form 8-K filed 2024-06-13 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 174,986,671 outstanding shares: 51.7% for, 1% withheld (52.7% of the company cast a for/withheld vote).

The 29 asset managers below cast 100% of the shares they voted on this item FOR (9,427,599 for, 0 against).

FOR 100%
FOR: 9,427,599 (100.0%)
Largest asset managers voting on “To elect eight directors to hold office until the 2025 annual meeting of shareholders and until their respecti” at LINEAGE CELL THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard6,355,4300 00For
BlackRock1,007,0020 00For
BRIDGEWAY FUNDS INC619,7570 00For
Charles Schwab365,9520 00For
Fidelity352,3870 00For
QUANTITATIVE MASTER SERIES LLC264,1910 00For
Lincoln Financial115,6000 00For
Equitable65,6450 00For
John Hancock55,0530 00For
Pacific Life38,3140 00For
T. Rowe Price26,2850 00For
Bridge Builder Trust26,1290 00For
DWS19,9320 00For
AIG/SunAmerica19,7080 00For
Principal17,8510 00For
Nationwide13,8620 00For
ProShares12,0550 00For
Calvert10,6560 00For
Victory Capital10,1700 00For
State Street9,4010 00For
TIAA5,1560 00For
PENN SERIES FUNDS INC5,1000 00For
Morgan Stanley4,0620 00For
Guggenheim2,5850 00For
Brinker Capital Destinations Trust2,2630 00For

Showing the 25 largest of 29 asset managers. See all 29 in the interactive database.

21. To elect eight directors to hold office until the 2025 annual meeting of shareholders and until their respective successors are duly elected and qualified: Dipti Amin

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2024-06-11.

Combines 3 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 90,605,789WITHHELD: 1,657,900

LINEAGE CELL THERAPEUTICS INC.’s own tally for this item (“Elect Director: Dipti Amin”): 90,605,789 for, 1,657,900 withheld, per its Form 8-K filed 2024-06-13 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 174,986,671 outstanding shares: 51.8% for, 1.0% withheld (52.7% of the company cast a for/withheld vote).

The 29 asset managers below cast 100% of the shares they voted on this item FOR (9,427,599 for, 0 against).

FOR 100%
FOR: 9,427,599 (100.0%)
Largest asset managers voting on “To elect eight directors to hold office until the 2025 annual meeting of shareholders and until their respecti” at LINEAGE CELL THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard6,355,4300 00For
BlackRock1,007,0020 00For
BRIDGEWAY FUNDS INC619,7570 00For
Charles Schwab365,9520 00For
Fidelity352,3870 00For
QUANTITATIVE MASTER SERIES LLC264,1910 00For
Lincoln Financial115,6000 00For
Equitable65,6450 00For
John Hancock55,0530 00For
Pacific Life38,3140 00For
T. Rowe Price26,2850 00For
Bridge Builder Trust26,1290 00For
DWS19,9320 00For
AIG/SunAmerica19,7080 00For
Principal17,8510 00For
Nationwide13,8620 00For
ProShares12,0550 00For
Calvert10,6560 00For
Victory Capital10,1700 00For
State Street9,4010 00For
TIAA5,1560 00For
PENN SERIES FUNDS INC5,1000 00For
Morgan Stanley4,0620 00For
Guggenheim2,5850 00For
Brinker Capital Destinations Trust2,2630 00For

Showing the 25 largest of 29 asset managers. See all 29 in the interactive database.

22. To elect eight directors to hold office until the 2025 annual meeting of shareholders and until their respective successors are duly elected and qualified: Don M. Bailey

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2024-06-11.

Combines 3 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%
FOR: 89,860,655WITHHELD: 2,403,034

LINEAGE CELL THERAPEUTICS INC.’s own tally for this item (“Elect Director: Don M. Bailey”): 89,860,655 for, 2,403,034 withheld, per its Form 8-K filed 2024-06-13 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 174,986,671 outstanding shares: 51.4% for, 1% withheld (52.7% of the company cast a for/withheld vote).

The 29 asset managers below cast 100% of the shares they voted on this item FOR (8,807,842 for, 0 against).

FOR 93%
FOR: 8,807,842 (93.4%)ABSTAIN: 619,757 (6.6%)
Largest asset managers voting on “To elect eight directors to hold office until the 2025 annual meeting of shareholders and until their respecti” at LINEAGE CELL THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard6,355,4300 00For
BlackRock1,007,0020 00For
BRIDGEWAY FUNDS INC00 619,7570Abstain
Charles Schwab365,9520 00For
Fidelity352,3870 00For
QUANTITATIVE MASTER SERIES LLC264,1910 00For
Lincoln Financial115,6000 00For
Equitable65,6450 00For
John Hancock55,0530 00For
Pacific Life38,3140 00For
T. Rowe Price26,2850 00For
Bridge Builder Trust26,1290 00For
DWS19,9320 00For
AIG/SunAmerica19,7080 00For
Principal17,8510 00For
Nationwide13,8620 00For
ProShares12,0550 00For
Calvert10,6560 00For
Victory Capital10,1700 00For
State Street9,4010 00For
TIAA5,1560 00For
PENN SERIES FUNDS INC5,1000 00For
Morgan Stanley4,0620 00For
Guggenheim2,5850 00For
Brinker Capital Destinations Trust2,2630 00For

Showing the 25 largest of 29 asset managers. See all 29 in the interactive database.

23. To elect eight directors to hold office until the 2025 annual meeting of shareholders and until their respective successors are duly elected and qualified: Michael H. Mulroy

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2024-06-11.

Combines 3 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 90,809,616WITHHELD: 1,454,073

LINEAGE CELL THERAPEUTICS INC.’s own tally for this item (“Elect Director: Michael H. Mulroy”): 90,809,616 for, 1,454,073 withheld, per its Form 8-K filed 2024-06-13 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 174,986,671 outstanding shares: 51.9% for, 0.9% withheld (52.7% of the company cast a for/withheld vote).

The 29 asset managers below cast 100% of the shares they voted on this item FOR (9,426,299 for, 0 against).

FOR 99.9%
FOR: 9,426,299 (100.0%)ABSTAIN: 1,300 (0.0%)
Largest asset managers voting on “To elect eight directors to hold office until the 2025 annual meeting of shareholders and until their respecti” at LINEAGE CELL THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard6,355,4300 00For
BlackRock1,007,0020 00For
BRIDGEWAY FUNDS INC619,7570 00For
Charles Schwab365,9520 00For
Fidelity352,3870 00For
QUANTITATIVE MASTER SERIES LLC264,1910 00For
Lincoln Financial115,6000 00For
Equitable65,6450 00For
John Hancock55,0530 00For
Pacific Life38,3140 00For
T. Rowe Price26,2850 00For
Bridge Builder Trust26,1290 00For
DWS19,9320 00For
AIG/SunAmerica19,7080 00For
Principal17,8510 00For
Nationwide13,8620 00For
ProShares12,0550 00For
Calvert10,6560 00For
Victory Capital10,1700 00For
State Street9,4010 00For
TIAA5,1560 00For
PENN SERIES FUNDS INC5,1000 00For
Morgan Stanley4,0620 00For
Guggenheim2,5850 00For
Brinker Capital Destinations Trust2,2630 00For

Showing the 25 largest of 29 asset managers. See all 29 in the interactive database.

24. To elect eight directors to hold office until the 2025 annual meeting of shareholders and until their respective successors are duly elected and qualified: Neal C. Bradsher

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2024-06-11.

Combines 3 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 90,181,941WITHHELD: 2,080,755

LINEAGE CELL THERAPEUTICS INC.’s own tally for this item (“Elect Director: Neal C. Bradsher”): 90,181,941 for, 2,080,755 withheld, per its Form 8-K filed 2024-06-13 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 174,986,671 outstanding shares: 51.5% for, 1% withheld (52.7% of the company cast a for/withheld vote).

The 29 asset managers below cast 100% of the shares they voted on this item FOR (8,795,886 for, 0 against).

FOR 93%
FOR: 8,795,886 (93.3%)ABSTAIN: 631,713 (6.7%)
Largest asset managers voting on “To elect eight directors to hold office until the 2025 annual meeting of shareholders and until their respecti” at LINEAGE CELL THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard6,355,4300 00For
BlackRock1,007,0020 00For
BRIDGEWAY FUNDS INC00 619,7570Abstain
Charles Schwab365,9520 00For
Fidelity352,3870 00For
QUANTITATIVE MASTER SERIES LLC264,1910 00For
Lincoln Financial115,6000 00For
Equitable65,6450 00For
John Hancock55,0530 00For
Pacific Life38,3140 00For
T. Rowe Price26,2850 00For
Bridge Builder Trust26,1290 00For
DWS19,9320 00For
AIG/SunAmerica19,7080 00For
Principal17,8510 00For
Nationwide13,8620 00For
ProShares12,0550 00For
Calvert00 10,6560Abstain
Victory Capital10,1700 00For
State Street9,4010 00For
TIAA5,1560 00For
PENN SERIES FUNDS INC5,1000 00For
Morgan Stanley4,0620 00For
Guggenheim2,5850 00For
Brinker Capital Destinations Trust2,2630 00For

Showing the 25 largest of 29 asset managers. See all 29 in the interactive database.

25. To ratify the appointment of WithumSmith+Brown, PC as our independent registered public accounting firm for our fiscal year ending December 31, 2024.

AUDIT-RELATEDMajority of the votes cast: yes

Meeting held 2024-06-11.

Combines 3 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 128,607,948AGAINST: 2,400,322

LINEAGE CELL THERAPEUTICS INC.’s own tally for this item (“Proposal 2: Shareholders ratified the appointment of WithumSmith+Brown, PC as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 by the following votes:”): 128,607,948 for, 2,400,322 against, per its Form 8-K filed 2024-06-13 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 174,986,671 outstanding shares: 73% for, 1% against (75% of the company cast a for/against vote).

The 29 asset managers below cast 100% of the shares they voted on this item FOR (9,427,599 for, 0 against).

FOR 100%
FOR: 9,427,599 (100.0%)
Largest asset managers voting on “To ratify the appointment of WithumSmith+Brown, PC as our independent registered public accounting firm for ou” at LINEAGE CELL THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard6,355,4300 00For
BlackRock1,007,0020 00For
BRIDGEWAY FUNDS INC619,7570 00For
Charles Schwab365,9520 00For
Fidelity352,3870 00For
QUANTITATIVE MASTER SERIES LLC264,1910 00For
Lincoln Financial115,6000 00For
Equitable65,6450 00For
John Hancock55,0530 00For
Pacific Life38,3140 00For
T. Rowe Price26,2850 00For
Bridge Builder Trust26,1290 00For
DWS19,9320 00For
AIG/SunAmerica19,7080 00For
Principal17,8510 00For
Nationwide13,8620 00For
ProShares12,0550 00For
Calvert10,6560 00For
Victory Capital10,1700 00For
State Street9,4010 00For
TIAA5,1560 00For
PENN SERIES FUNDS INC5,1000 00For
Morgan Stanley4,0620 00For
Guggenheim2,5850 00For
Brinker Capital Destinations Trust2,2630 00For

Showing the 25 largest of 29 asset managers. See all 29 in the interactive database.

Largest LINEAGE CELL THERAPEUTICS INC. shareholders voting in 2023-2024

Ranked by the number of LINEAGE CELL THERAPEUTICS INC. shares each manager voted on the most widely held ballot item of the 2023-2024 meeting, shown as a share of the 174,986,671 shares outstanding at the time of that meeting.

Top LINEAGE CELL THERAPEUTICS INC. shareholders by shares voted, 2023-2024
#Asset manager % of shares outstanding
1Lazard 84.58%
2Vanguard 3.04%
3BlackRock 2.96%
4Laurion Capital Management LP 1.10%
5State Street 1.04%
6RAFFLES ASSOCIATES LP 0.91%
7GEODE CAPITAL MANAGEMENT, LLC 0.62%
8JPMorgan 0.60%
9Fidelity 0.57%
10BRIDGEWAY FUNDS INC 0.44%

Reported LINEAGE CELL THERAPEUTICS INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

LINEAGE CELL THERAPEUTICS INC. beneficial owners on record for the 2023-2024 proxy season
Holder % outstanding Disclosure
Neal C. Bradsher 23.99% DEF14A
Broadwood Partners, L.P. 23.81% 13D
Vanguard Group 5.15% 13F
Brian M. Culley 3.35% DEF14A
Geode Capital 1.86% 13F
BlackRock 1.27% 13F
State Street 1.24% 13F
George A. Samuel III 0.78% DEF14A
Northern Trust 0.70% 13F
Morgan Stanley 0.58% 13F

Percentages above are of 174,986,671 shares outstanding, as reported by LINEAGE CELL THERAPEUTICS INC. on its Form 10-Q dated 2023-08-04 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from LINEAGE CELL THERAPEUTICS INC.’s 10-Q dated 2023-08-04. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At LINEAGE CELL THERAPEUTICS INC.'s 2 shareholder meetings in the 2023-2024 proxy season (held 2023-09-06 and 2024-06-11), 144 asset managers reported how they voted in their SEC Form N-PX filings, covering 2,205 separate fund positions. Their filings are grouped here into 25 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item of the season, voted at the meeting held 2023-09-06 — TO INDICATE, ON AN ADVISORY BASIS, THE PREFERRED FREQUENCY OF HOLDING AN ADVISORY VOTE ON THE… — FOR was 89% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: LINEAGE CELL THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2023-09-07.

LINEAGE CELL THERAPEUTICS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.